Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + cobimetinib + vemurafenib versus placebo + cobimetinib + vemurafenib in previously untreated BRAF V600 mutation-positive advanced melanoma
2016-002482-54Phase 3Active
- Sponsor
- Roche
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma and Nonhematologic neoplasms comparing Atezolizumab + cobimetinib + vemurafenib with Placebo + cobimetinib + vemurafenib (2 arms). Primary endpoint: Progression-free survival. Started Sep 2016; status: active.
02
Drugs
atezolizumabcobimetinibvemurafenib
03
Conditions
melanomaNonhematologic neoplasms
Beyond the preview
Go deeper on 2016-002482-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002482-54.